This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. INDIANAPOLIS — Indianapolis-based Eli Lilly ...
WALTHAM, Mass., May 21, 2024 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic ...
Forbes contributors publish independent expert analyses and insights. I give biotech insiders an edge at Timmerman Report. Integrins were a big deal in the early days of biotech in the 1980s and 1990s ...
AbbVie is ditching work on all the alpha V beta 6 (αvβ6) inhibitors that it paid $20 million to license from Morphic Therapeutic in 2020. The Big Pharma is culling the work because of a suspected ...
WALTHAM, Mass.--(BUSINESS WIRE)--Morphic Therapeutic, a biotechnology company developing a new generation of oral integrin drugs, announced today that it has completed a $51.5 million Series A ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback